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Abstract
Background: The development of resistance is a problem shared by both classical chemotherapy and targeted
therapy. Patients may respond well at first, but relapse is inevitable for many cancer patients, despite many
improvements in drugs and their use over the last 40 years.
Review: Resistance to anti-cancer drugs can be acquired by several mechanisms within neoplastic cells, defined as
(1) alteration of drug targets, (2) expression of drug pumps, (3) expression of detoxification mechanisms, (4)
reduced susceptibility to apoptosis, (5) increased ability to repair DNA damage, and (6) altered proliferation. It is
clear, however, that changes in stroma and tumour microenvironment, and local immunity can also contribute to
the development of resistance. Cancer cells can and do use several of these mechanisms at one time, and there is
considerable heterogeneity between tumours, necessitating an individualised approach to cancer treatment. As
tumours are heterogeneous, positive selection of a drug-resistant population could help drive resistance, although
acquired resistance cannot simply be viewed as overgrowth of a resistant cancer cell population. The development
of such resistance mechanisms can be predicted from pre-existing genomic and proteomic profiles, and there are
increasingly sophisticated methods to measure and then tackle these mechanisms in patients.
Conclusion: The oncologist is now required to be at least one step ahead of the cancer, a process that can be
likened to ‘molecular chess’. Thus, as well as an increasing role for predictive biomarkers to clinically stratify patients,
it is becoming clear that personalised strategies are required to obtain best results.
Keywords: Cancer, Chemotherapy, Resistance, Tyrosine kinase inhibitor, Apoptosis, Proliferation, DNA damage,
Detoxification, Microenvironment, Heterogeneity
Background
Resistance often follows initial responses to chemother-
apy. This phenomenon was first noted for alkylating
agents in the 1940s [1–3], and although combinations of
chemotherapeutic agents led to improved survival [4–6],
resistance has remained a problem for classical chemo-
therapy and newer targeted agents [7]. Cell culture
methods allowed study of the phenomenon in vitro, and
cell lines have been widely used to explore the mecha-
nisms involved [7, 8]. Classical multidrug resistance
(MDR) was recognised early in the development of
chemotherapy and MDR1 (ABCB1, PgP) was identified
in 1986 [9], followed by other drug efflux pumps [10].
The rapidity with which cancer cells can develop re-
sistance to chemotherapy is startling. Using samples
from an early neoadjuvant breast cancer trial, we were
able to show a considerable difference in chemosensitiv-
ity between cancer cells obtained prior to and following
four cycles of CMF chemotherapy [11]. The dogma that
resistance arose from overgrowth of resistant cell clones
due to new mutations was clearly incorrect. We went on
to show that tumour-derived cells in primary cell culture
down-regulate drug targets and up-regulate resistance
mechanisms compared with untreated cells [12]. It is
now clear that cancer chemosensitivity is governed by
the relative expression of sensitivity and resistance
mechanisms, determined by both genetic and environ-
mental factors within tumours [13–15].
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Initially many tumours appear to respond to treat-
ment but, as not all the neoplastic cells are killed,
this residual population enables regrowth of tumours
that no longer respond to a wide variety of drugs
[11]. This is cannot be explained by just one mechan-
ism: extreme drug resistance is far more likely to be
derived from both gene regulation and mutation.
Thus, although in some cases acquired drug resist-
ance may appear to be due to specific mutations, in
many cases rapid resistance originates from multiple
non-mutational, non-genetic mechanisms [12, 14, 15].
As targeted agents such as tyrosine kinase inhibitors
(TKIs) came into practice, it was rapidly noted that these
too exhibited the development of resistance, but usually
a much slower rate [16–18]. In GIST, imatinib resistance
was been found to be due to new mutations, and these
often arise in one deposit while others continue to re-
spond [19–24]. Similar results are seen for other
mutation-targeted agents including epidermal growth
factor receptor (EGFR) inhibitors in non-small cell lung
cancer (NSCLC) [25–28], BRAF inhibitors in melanoma
[29, 30], and HER2 inhibition in breast cancer [31, 32].
A tumour can compensate for EGFR (HER1) blockade
through the activation of alternative signaling pathways
such as amplification of MET as well as through changes
in tumour microenvironment [33]. EMT has also been
reported in NSCLC samples from patients who had de-
veloped resistance to EGFR inhibition [33], and some
patients develop small cell lung cancer, via neuroendo-
crine differentiation [34].
Mechanisms of resistance
The principles underlying the development of anti-
cancer drugs resistance apply across all the anti-cancer
drugs we have studied, though some are more common
in different drug-tumour combinations. The mecha-
nisms fall into a number of distinct categories (Fig. 1),
and often occur together, complicating attempts to com-
bat them:
(1)Alteration of Drug Targets: While it is common to
separate drugs used in chemotherapy from newer
agents targeting molecular pathways, it is of course a
truism that all drugs have targets. These targets can
be altered by cells in a number of ways. Rapid
down-regulation of a target gene expression is an
obvious ploy, exemplified by the effect of doxorubicin
on topoisomerase IIα [12], but more subtle alteration
Fig. 1 We recognise six hallmarks of anti-cancer drug resistance. Cancer cells may alter drug targets by mutation or reduced expression; upregulate
the expression of drug pumps; increase the activity of expression of drug detoxification mechanisms; reduce their susceptibility to apoptosis; alter their
level of proliferation; and increase their ability to repair DNA damage. All of these may be employed at once, but there is considerable heterogeneity
between tumours, requiring an individualised approach to cancer treatment
Cree and Charlton BMC Cancer  (2017) 17:10 Page 2 of 8
of drug targets by mutation is also common particu-
larly in response to targeted agents such as receptor
tyrosine kinase inhibitors [21, 22, 25, 30, 32]. If the
target is part of a pathway activated by other mole-
cules, then the cell may activate an alternative mo-
lecular mechanism – mutation of EGFR in ALK
fusion gene positive lung cancer is a good example
[28, 35, 36].
(2)Expression of drug efflux pumps: The ATP-binding
cassette (ABC) superfamily of proteins includes a
number of membrane proteins able to transport a
wide diversity of substrates. Besides an ability to
transport of toxins out of cells, other substrates in-
clude amino acids, peptides, sugars, lipids, steroids,
bile salts, nucleotides and endogenous metabolites
[10]. These pumps act to protect cells by ejecting a
wide variety of toxins. Although in bacteria this
toxin might be an antibiotic, in human cancer it is
often an anticancer drug. Classical drug resistance is
mediated by the MDR1 (ABCB1) gene, which en-
codes a membrane-based xenobiotic pump molecule,
known as phenolic glycoprotein (PgP). This pump is
relatively promiscuous and ejects drugs from the cell
at a rate that may exceed their entry, rendering the
cell resistant. One of the more important molecules
of the blood-brain barrier, it has been much studied.
This in turn led to the discovery of numerous other
pumps, and the human genome contains 49 ABC
transporter molecules [10], many of which can
pump drugs. Besides MDR1 the best known are
multidrug resistance related protein (MRP1, ABCC1)
and breast cancer related protein (BCRP, ABCG2).
Pharmaceutical chemists now design drugs with this
mind, so that pump mechanisms are less problem-
atic than they were, though even some TKIs, includ-
ing gefitinib and erlotinib [37, 38], are pumped.
Metabolite and nucleotide pumps have also been
found to be of importance, and genes such as
hENT1 have been reported to be important media-
tors of chemosensitivity in gene expression studies
[13–15]. Rapid up-regulation of drugs pumps can
occur in cancer cells and lead to resistance [12].
(3)Expression of detoxification mechanisms: Drug
metabolism occurs at the host level, where it
underlies the pharmacokinetics of many drugs, and
within cancer cells themselves, where there may be
considerable heterogeneity. Molecules such as
gluthathione S-transferase (GSTπ) are well known to
be up-regulated in some cancers and a potential
cause of resistance [12, 39]. It is possible that conju-
gation and excretion of drugs at the luminal surface
of some well-differentiated adenocarcinomas may
explain the relationship between differentiation and
drug sensitivity to some drugs, but this remains
uncertain [40–42]. Altered local drug metabolism
and detoxification are key resistance mechanisms
across many cancers. As an example, these processes
have been investigated in the plasma cell cancer,
Multiple Myeloma (MM), where a majority of pa-
tients repeatedly relapse and finally succumb to the
disease [43]. The expression of 350 genes encoding
for uptake carriers, xenobiotic receptors, phase I and
II drug metabolising enzymes and efflux transporters
was assessed in MM cells of newly-diagnosed pa-
tients. There was a global downregulation of genes
encoding for xenobiotic receptors and downstream
detoxification genes in patients with an unfavourable
outcome. However, there was a higher expression of
genes encoding for the aryl hydrocarbon receptor
nuclear translocator and Nrf2 pathways as well as
the ABC transporters in these patients [43].
(4)Reduced susceptibility to apoptosis and cell death:
Apoptosis was recognised as a unique form of cell
death by Currie and others in the 1970s [44, 45]. It
attracted the attention from pathologists, but it was
not until experiments by Gerard Evan et al. [46–48]
that it became clear that avoidance of apoptosis
underpinned the development of cancer and was an
important resistance mechanism for cancer cells to
both chemotherapy [8, 47, 48] and agents targeting
signaling pathways [49–51]. Other forms of cell
death may also be triggered by anti-cancer drugs, in-
cluding necrosis, necroptosis, and autophagy [52]. In
all cases, the key feature in resistance seems to be
survival signalling which prevents cell death. Not all
forms of cell death are the same, and the level of
damage required to achieve cell death is variable.
This particularly true of autophagy, which can either
promote chemosensitisation or chemoresistance
[53]. In some cases, its inhibition can chemosensitise
tumours [54]. Necroptosis is a caspase-independent
form of cell death induced by receptor-interacting
protein kinases (RIP1 and RIP3) or mixed lineage
kinase domain-like protein (MLKL). Its importance
in cancer treatment is controversial, but its induction
may circumvent anti-apoptotic mechanisms [55].
(5)Increased ability to repair DNA damage: As cancers
must acquire permanent genomic mutations, cancer
can be viewed as a disease of DNA repair as changes
in these genes produce the mutator phenotype
essential the for the acquisition of further mutations.
Once a mutation is acquired cancers often become
addicted to a different DNA repair pathway. A good
example of this is exemplified by BRCA1/2. As
BRACA1/2 are key components of a DNA double
strand repair pathway these cancers become
dependent on another DNA repair component,
PARP1, for replication fork progression [56, 57].
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Inhibition of PARP1 in these cancer cells is
catastrophic and results in their death. This is the
concept of synthetic lethality [58] and has been
proposed as a potential Achilles heel in a cancer
cell’s defense. Although this concept may enable the
clinician to increase the therapeutic index between
cancer and normal cells, it is expected that these
approaches will also have the potential to develop
resistance. DNA damage is recognised by cells, and
if they cannot repair the damage, this leads to
apoptosis [12, 59]. If apoptotic potential is reduced,
then cells can survive considerable DNA damage,
but an alternative is to up-regulate DNA repair [59].
Many cells of course do both.
(6)Altered proliferation: The normal response to DNA
damage that cannot be repaired is apoptosis, but as
Gerard Evan showed in diploid fibroblasts, the
threshold for death is much higher in cells that are
not growing [46]. Transient reduction in growth is
mediated in part by P53 [60]. Levels of P53 rise and
at first simply reduce cell cycle, only tipping over to
stimulate apoptosis at a certain threshold [60].
Other factors
In addition to these key mechanisms there are several
other factors external to the neoplastic cell that can
contribute to resistance. These include the influence
of the tumour stroma and microenvironment [61, 62],
the role of tumour-initiating cells as part of intra-
tumoural heterogeneity, autophagy [63] and intra-
tumoural heterogeneity [64].
Although much of the field of cancer drug resistance
has been focused on the tumour cell and its ability to
develop resistance, the ‘host’ can also play a major role
in promoting resistance to therapy. Chemotherapy, tar-
geted therapies and radiotherapy all lead to the recruit-
ment of different host cells and factors to the tumour
microenvironment. This host response can then contrib-
ute to resistance by inducing various cellular and mo-
lecular pathways that support the tumour, for example
by driving tumour cell proliferation (Altered Prolifera-
tion) or survival (Reduced susceptibility to apoptosis).
As the tumour microenvironment is heterogeneous it
can help support a variety of resistance mechanisms. For
example various cellular pathways are affected by
tumour hypoxia, and thus tissue hypoxia can contribute
to development of resistance [61].
Tumour-initiating cells may also play a key role in
tumour recurrence as these cancer stem cells (CSCs) are
able to utilise a number of mechanisms to evade chemo-
therapy (e.g. expression of ABC transporters, enhanced
expression of aldehyde dehydrogenase, expression of pro-
survival proteins altered DNA damage response and al-
tered signaling pathways) [65, 66]. As a result of their
ability to better tolerate drug exposure, CSCs are often re-
fractory to drug treatment. For example, integrin αvβ3 ex-
pression in multiple types of solid tumour stem cells
controls a pro-survival pathway involving activation of
KRAS, which may contribute to TKI drug resistance [67].
Autophagy is a complex issue as induction of autoph-
agy can have both a pro-death and a pro-survival role
[63, 68]. Thus autophagy can influence both the antican-
cer efficacy of drugs as well as contribute to drug resist-
ance. In its role as a cellular housekeeper autophagy
removes damaged organelles and by recycling macro-
molecules can protect against cancer formation. How-
ever, in established tumours this ‘protective’ role can
switch to a pro-survival function as, when cancer cells
are stressed, autophagy can enable the tumour to re-
spond to its environmental conditions through reducing
growth and by increasing the catabolic turnover of un-
necessary proteins and organelles. Under these condi-
tions inhibition of autophagy may actually help
overcome resistance to chemotherapy [68].
Tumours show considerable heterogeneity in the ex-
tent to which they use these mechanisms [12, 15]: and it
is likely that there is also considerable intra-tumoural
heterogeneity, given the presence of multiple clones
within tumours [64].
Use of multiple mechanisms
Cancers can employ several resistance mechanisms, ei-
ther sequentially or concurrently to evade drug treat-
ment. Four examples are described to illustrate this
point, including classical chemotherapy and targeted
agents:
1. Topoisomerase II inhibitors remain a mainstay of
both haematological and solid tumour therapy,
but their clinical efficacy is often limited by
resistance. Many mechanisms may contribute to
this resistance including reduced drug
accumulation and/or increased efflux, site specific
mutations affecting drug-induced topo II mediated
DNA damage, post-translational modifications
resulting in altered DNA damage and downstream
cytotoxic responses [12, 15].
2. Anti-HER2 antibodies such as Herceptin develop
acquired resistance through a variety of
mechanisms, including activation of tyrosine
kinase in CSCs, upregulation of HER3, activating
mutations in the p110a subunit of PIKK
(PIK3CA), enhanced HER-ligand autocrine signal-
ing and alterations in apoptotic pathways [69].
HER3 has now also been proposed as potentially
driving survival of HER2+ cells once they have
developed resistance to HER2 inhibitors such as
lapatinib and trastuzumab [69].
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3. Bortezomib was the first proteasome inhibitor to
enter practice. Again a wide range of mechanisms
have been reported in acquired resistance to this
drug, which has an important role in the treatment
of several haematological cancers. These include
mutations in proteasome subunits, unfolded protein
response, XBP1 and MARCKS proteins, aggresomes,
the role of constitutive and immunoproteasomes,
alterations in pro-survival signalling pathways,
changes in bone marrow microenvironment and
autophagy as well as other multidrug resistance
mechanisms [70, 71].
4. Antibody-drug conjugates can also be limited by
acquired resistance [72]. As with small molecules,
this resistance is multifactorial and can include
altered interaction with the target, altered apoptosis
pathways and altered survival pathways. In addition,
the payload for any antibody drug conjugate
approach is likely to be sensitive to the same range
of resistance mechanisms described for small
molecule drugs.
It is clear that understanding these mechanisms has
enabled the field to undertake more rational develop-
ment of the next generation of drugs to overcome clin-
ical resistance. Beyond chemical modification of a drug,
advances in other technologies are also looking promis-
ing. For example nanoparticle delivery systems to allow
better targeting or addressing specific molecular alter-
ations in resistant tumours [73]. It may also be possible
to develop multifunctional nanoparticles able to simul-
taneously target multiple resistance mechanisms.
Strategies to overcome resistance
Understanding of resistance mechanisms has now ad-
vanced to the point where experimental approaches
can now start to predict clinical drug resistance. In
vitro these approaches include target-based mutagen-
esis, use of isogenic tumour cell lines, both gain and
loss of function resistance screens, and in depth ana-
lysis (cellular, genomic and molecular) of drug-
resistant tumours. Further information will be gained
from both genetically-engineered mouse models,
patient-derived xenografts, and ex vivo primary cell
culture models. A number of strategies have been
used in cancer treatment to overcome the problem of
resistance.
1. The development of new synthetic analogues of
existing drugs has been the usual response to try to
circumvent resistance. It is possibly best exemplified
in the vinca alkaloid derived drugs, where greater
potency has been achieved by chemical alteration of
molecules [74, 75]. In some cases however, this
approach has been less than successful, as it tends to
increase toxicity.
2. Combinations have been used in oncology since
multiple drugs became available. Most combinations
have been developed empirically, on the basis that if
two drugs are active, then the combination should be
more active still. This has been a successful approach,
but as the number of possible combinations has risen,
the number of expensive clinical trials required to
fine-tune such combinations has made this approach
less attractive. Cell lines have been used to design
combinations, with some success, but the reality is
that highly passaged cell lines are poor models of can-
cer cell behavior [76, 77]. We have previously used
primary cell culture to develop new combinations,
with considerable success [78].
It is clearly important to stratify patients based on
whether they are likely to respond to a particular
therapy or combination. Although cell lines can
provide a useful first step they are unable to
effectively model the complex tumour–stroma
interactions that contribute to the development of
drug resistance. It is now suggested that combining
therapies that target two or more orthogonal,
‘independent’ pathways, will be preferable to
attempting to hit two or more targets on the same
pathway. It is hoped that this approach will reduce
the tumour’s ability to mount an effective resistance
campaign.
3. Sequential strategies have much to recommend
them, both to increase efficacy and reduce toxicity.
Despite some success, relatively few sequential
combinations have entered clinical practice, as until
recently the molecular understanding of their
efficacy has been lacking [79]. DNA and RNA
sequencing technologies are now at a point where
they can be used as companion diagnostic
technologies, and the effects of sequential drug
administration can be predicted [80].
4. Synthetic lethality is used to describe a mechanistic
approach to combination and sequence design.
Tumour-specific genetic changes can make cancer
cells more vulnerable to synthetic-lethality strategies
and so enable the clinician to target tumour cells
while sparing normal cells. These mutations in can-
cer genes may be either loss or gain of function and
the concept can be extended to contextual synthetic
lethality to include defects in metabolic processes
and rewiring signaling networks and tumour-
associated hypoxia [81]. Nevertheless, even with a
new generation of novel targeted cancer therapies
based on the concept of synthetic lethality, the po-
tential for secondary acquired resistance remains.
Mutation or inactivation of P53 is usually thought to
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be anti-apoptotic, allowing cells to avoid the induc-
tion of apoptosis. However, chemosensitivity experi-
ments in ovarian cancer showed that this was not
always the case [82], and subsequent studies have
shown that under certain conditions, mutation of
P53 can confer susceptibility to apoptosis [60]. It is
increasingly clear that such approaches to synthetic
lethality are achievable with sufficient knowledge of
the molecular makeup of individual cancers [60]. In
high grade serous ovarian cancer, characterised by
P53 mutation, 20% of patients have BRCA1 and
BRCA2 mutations rendering them susceptible to
PARP inhibitors, and methylation of the BRCA1 pro-
moter has a similar effect [83]. Drug development
and companion diagnostic development strategies
need to be aligned, and tested in a variety of pre-
clinical settings before use in man.
5. Immunotherapy has long been suggested as a
solution to many of the problems of anti-cancer
drug resistance. The advent of anti-CTLA antibody
treatment with ipilimumab in melanoma [84]
showed that the promise was likely to be fulfilled,
and the success of anti-PD1 and anti-PDL1 anti-
bodies alone and in combination with anti-CTLA4
antibody treatment is nothing short of a revolution
in melanoma and lung cancer, to mention but two
target cancers of the many that are likely to benefit
from these agents. Understanding of resistance to
these agents is at an early stage [85], and the benefits
of combination or sequential use of immunothera-
peutics with chemotherapy or targeted agents has
yet to be established. However, it is already clear that
PDL1 expression by the neoplastic cells is useful as a
companion diagnostic, despite difficulties of imple-
mentation [86]. Neo-antigen load is related to muta-
tional load [87], and cancers with high mutational
load seem to respond well to immunotherapy [88, 89].
It is entirely possible that accurate immune profiling
of tumours will require multiple methods.
Genetic and epigenetic events, as well as extracellular
signals, can activate pathways that enable cancer cells to
become chemoresistant to therapeutic agents. This situ-
ation has encouraged a more systematic approach to
identifying those signaling pathways that might confer
resistance to cancer drugs. This approach will not only
help stratify patients into groups either more or less
likely to respond, but also will help design drug combi-
nations that act simultaneously on multiple cancer cell
dependencies and resistant pathways.
Molecular pathology
Alterations of proteins and nucleic acids can be identi-
fied with increasing accuracy, and their concentration
measured accurately and precisely using a variety of dif-
ferent methods [90, 91], some of which can be applied
to blood samples without ever needing a biopsy of the
tumour. Implementation of these methods in pathology
departments is proceeding rapidly [90], and the mea-
surements are increasingly used by oncologists to tailor
treatment to individual measurements. The challenge to
the diagnostic pathologist is to go beyond diagnosis to
provide the information needed to treat the patient [92],
while the challenge to the oncologist is to understand
the information provided and adopt a strategy that gives
the patient the longest possible survival with the greatest
possible quality of life [93, 94]. The use of specific TKIs
is often guided by closely linked companion diagnostics,
such as EGFR or KRAS mutation status according to the
licensed indication [92]. Late resistance mechanisms
often involve further mutations, and these may require
more extensive testing. In contrast to companion diag-
nostics, the term ‘complementary diagnostics’ describes
a broader group of diagnostics associated with a class of
drugs, unconstrained by drug license and used to guide
therapy [95]. As the number of drugs and targets in-
crease, use of complementary diagnostics are likely to be
required to optimise therapy, based on methods such as
targeted next generation sequencing [80].
Conclusions
Cancer teams need to learn to play molecular chess – ef-
fectively outthinking the cancer’s likely response to any
treatment used, and to be ready for it. The tools provided
by the pharmaceutical industry to allow this have never
been better, and coupled with increasingly sophisticated
radiotherapy and surgery, allow many patients to survive
for years and even decades with cancers that would have
killed them rapidly just 30 years ago. The principles of
drug resistance – or perhaps the rules of molecular chess
– are increasingly clear and can improve patient care.
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